Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Canada Postdoctoral Research Award (CPRA) program

Université de Montréal

$140,000.00

Defining lineage-specific drivers of growth and drug resistance in melanoma through Sonata, a next-generation CRISPRa platform

FY 2025-26

Summary
Melanoma, a form of skin cancer, is one of the most lethal and difficult to treat cancers, resulting in the deaths of 1,300 Canadians per year. A better understanding of what genes allow melanoma to grow and acquire resistance to existing therapies will allow the design of new treatments to improve patient outcomes. Sonata is a recently developed technology that, for the first time, allows the consistent and reproducible activation of any of the 20,000 human genes in a human cell. Using Sonata, we will test the impact on cell growth and survival of individually activating every gene in different kinds of melanoma cells. The cells will be grown either untreated, or in the presence of drug combinations commonly used to treat melanoma. The same experiments will also be carried out on normal skin cells. This will reveal what genes and pathways drive melanoma growth, death, and drug resistance, and how these differ from normal cells. This research will allow the development of treatments that inhibit melanoma growth, induce cell death, and sensitize cancerous cells to drugs, while leaving normal cells unharmed.
Program
Canada Postdoctoral Research Award (CPRA) program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
537898
Name
Sharon David M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Defining lineage-specific drivers of growth and drug resistance in melanoma through Sonata, a next-generation CRISPRa platform
Programtype2
Fellowship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Cell Growth And Plasticity; Drug Resistance; Functional Genetics; Genome-Wide Crispra Library Screening; Melanoma; Single Cell Rna Sequencing
Abstract
Melanoma, a form of skin cancer, is one of the most lethal and difficult to treat cancers, resulting in the deaths of 1,300 Canadians per year. A better understanding of what genes allow melanoma to grow and acquire resistance to existing therapies will allow the design of new treatments to improve patient outcomes. Sonata is a recently developed technology that, for the first time, allows the consistent and reproducible activation of any of the 20,000 human genes in a human cell. Using Sonata, we will test the impact on cell growth and survival of individually activating every gene in different kinds of melanoma cells. The cells will be grown either untreated, or in the presence of drug combinations commonly used to treat melanoma. The same experiments will also be carried out on normal skin cells. This will reveal what genes and pathways drive melanoma growth, death, and drug resistance, and how these differ from normal cells. This research will allow the development of treatments that inhibit melanoma growth, induce cell death, and sensitize cancerous cells to drugs, while leaving normal cells unharmed.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Sharon, David M
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~